Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

In this Phase II, single-arm, nonrandomized clinical trial that included 28 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, the complete molecular remission rate after CD19 chimeric antigen receptor (CAR) T cell therapy was 85%.